Stock Events

Stock Events

Search...

Entheon Biomedical

€0.01

1

+€0+16.67% Thursday 07:31

Statistics

Day High

0.01

Day Low

0.01

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

281,483

P/E Ratio

0.06

Dividend Yield

-

Dividend

-

Earnings

31AugConfirmed

Q4 2020

Q1 2021

Q2 2021

Q3 2021

Q4 2021

Q1 2022

Q2 2022

-0.05

-0.03

-0.01

0.01

Expected EPS

N/A

Actual EPS

0.006

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1XU1.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Compass Pathways

Compass Pathways operates in the psychedelic medicine sector, focusing on psilocybin therapy for depression, similar to Entheon's focus on psychedelic therapies.

Mind Medicine works on developing psychedelic-inspired therapies, directly competing with Entheon's approach in mental health treatment.

ATAI Life Sciences N.V.

ATAI Life Sciences is a biotech company developing psychedelic and non-psychedelic compounds for mental health disorders, overlapping with Entheon's market.

GH Research focuses on developing 5-MeO-DMT therapies for depression, a direct competitor in the psychedelic treatment space.

Revive Therapeutics

Revive Therapeutics explores psilocybin-based therapies, which is a direct competition to Entheon's psychedelic research and development.

Mydecine Innovations

Mydecine Innovations Group focuses on developing and commercializing psychedelic medicines, competing in the same niche as Entheon.

Seelos Therapeutics

Seelos Therapeutics works on projects including ketamine-based treatments, which competes with Entheon's psychedelic-based therapeutic approaches.

About

Entheon Biomedical Corp. operates as a biotechnology research and development company. It engages in developing of products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.

Show more...

CEO

Mr. Timothy Ko

Employees

2

Country

CA

ISIN

CA29383X1033

WKN

000A2QJBZ

Listings